ArticleIn silico pharmacology2025
Exploring capsaicin as a multi-target agent for osteoporosis through computational insights.
Article in In silico pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis remains a significant global health challenge, characterized by an imbalance between bone formation and resorption, leading to compromised skeletal integrity and increased fracture risk. Capsaicin, the primary bioactive component in chilli peppers, has garnered attention for its potential role in modulating bone health due to its multifaceted pharmacological properties. This study investigates the molecular mechanisms underlying capsaicin's influence on osteoporosis-related pathways using a computational approach. Bioinformatics analyses identified key hub targets and signaling pathways linked to capsaicin's therapeutic effects. Employing molecular docking and dynamic simulations, we assessed capsaicin's binding interactions with critical protein targets, providing detailed insights into its structural and energetic properties. Notably, capsaicin demonstrated specific interactions with inflammation-related mediators and matrix-degrading enzymes, highlighting its capacity to interfere with processes driving bone loss. The findings suggest that capsaicin exerts dual-action effects by attenuating inflammation and suppressing bone degradation, positioning it as a promising candidate for osteoporosis treatment. This research enhances our understanding of capsaicin's role in maintaining skeletal health and underscores its potential as a therapeutic agent. Furthermore, the study provides a robust framework for future preclinical studies to validate its efficacy and optimize its application in clinical settings for managing osteoporosis. Supplementary Information: The online version contains supplementary material available at 10.1007/s40203-025-00400-x.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.